You are here

Article Text

Article menu

Download PDFPDF

Friday 07 October 2022 from 13:00 to 14:10
PO.8 E- poster session 8: skin manifestations, SLE and infections, fertility and pregnancy, imaging
PO.8.175 Antimalarial drugs and electrocardiographic alterations in patients with systemic lupus erythematosus
  1. C Riesco Barcena1,
  2. S Leal Rodríguez1,
  3. ME Acosta de la Vega2,
  4. E Grau García1,
  5. C Pávez Perales1,
  6. AV Huaylla Quispe1,
  7. M De la Rubia1,
  8. P Muñoz Martínez1,
  9. L Mas Sánchez1,
  10. I Martínez Cordellat1,
  11. C Nájera Herranz1,
  12. R Negueroles Albuixech1,
  13. F Ortiz-Sanjuán1,
  14. E Vicens Bernabéu1,
  15. I Cánovas Olmos1,
  16. JJ Fragio Gil1,
  17. L González Puig1,
  18. J Oller Rodríguez1,
  19. J Ivorra Cortés1 and
  20. JA Román Ivorra1
  1. 1Servicio de Reumatología. Hospital Universitario y Politécnico La Fe. Valencia. España
  2. 2Servicio de Reumatología. Instituto Musculoesquelético Europeo. Valencia. España

Abstract

.Background During the first months of the Sars-CoV-2 pandemic, antimalarial drugs were the central axis of the treatment of patients with acute respiratory infection. After that, several studies reported a risk of prolongation of corrected QT interval (QTc) at the electrocardiogram (ECG).

Historically, these drugs, have been the common denominator in the treatment of patients with Systemic Lupus Erythematosus (SLE).

Objectives To analyze the possible relationship between the use of antimalarial drugs and the electrocardiographic alterations in patients diagnosed with SLE.

Methods Cross-sectional study in patients diagnosed with SLE (SLICC 2012). In all of them, we performed a 12-lead ECG at rest. We measured the QT interval: manually and automatically, and its correction was made according to the Hodge formule (QTc)

Results 91 patients diagnosed with SLE were included in the study. Of the total of patients included in the study, 64 were in current treatment with an antimalarial drug, with a mean of 9.09 (5.73) years of treatment, and a mean cumulative dosage of 813.16 (436.12) gr.

Of the patients on current treatment with antimalarial drugs, 4.69% had a prolonged QTc, compared to 3.7% of the patients without current treatment with these drugs.

View this table:
Abstract PO.8.175 Table 1

Principal characteristics of the patients included in our study

We analyzed the possible relationship between the QTc interval, the current treatment with antimalarial drugs, and the cumulated dosage of this medication. We corrected the lineal regression models by the years of disease evolution, the presence or absence of known heart disease, the women gender, and other treatments such as antiarrhythmics or beta-blockers.

We found a statistically significant association between taking antimalarial drugs and the elongated QTc interval (p= 0,001). Nevertheless, in the multivariate analysis, we did not find a significant relationship between the ECG alterations and the treatment with antimalarial drugs.

Conclusions In our study, we did not observe a direct relationship between the intake of antimalarial drugs and the alteration of the corrected QT interval.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

https://doi.org/10.1136/lupus-2022-elm2022.194

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.